Nrf2 ameliorates diabetic nephropathy progression by transcriptional repression of TGFβ1 through interactions with c-Jun and SP1

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1839, Issue 11, 2014, Pages 1110-1120

  Gao, Pan ^a   Li, Liliang ^a   Ji, Lili ^b   Wei, Yingze ^a   Li, Hui ^a   Shang, Guoguo ^a   Zhao, Zhonghua ^a   Chen, Qi ^a   Jiang, Tao ^a   Zhang, Nong ^a  

^a FUDAN UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

C Jun; Diabetic nephropathy; Nrf2; ROS; SP1; TGF 1

Indexed keywords

PROTEIN C JUN; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; NFE2L2 PROTEIN, MOUSE; PROTEIN BINDING; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESANGIUM CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BINDING; PROTEIN INTERACTION; REGULATORY MECHANISM; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DOWN REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOWN-REGULATION; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NF-E2-RELATED FACTOR 2; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; SP1 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84907555730     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.06.018     Document Type: Article

References (42)

1. Tu S.T., Chang S.J., Chen J.F., Tien K.J., Hsiao J.Y., Chen H.C., Hsieh M.C. Prevention of diabetic nephropathy by tight target control in an Asian population with type 2 diabetes mellitus: a 4-year prospective analysis. Arch. Intern. Med. 2010, 170:155-161.
2. Alsaad K.O., Herzenberg A.M. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J. Clin. Pathol. 2007, 60:18-26.
3. Parving H.H., Lewis J.B., Ravid M., Remuzzi G., Hunsicker L.G. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006, 69:2057-2063.
4. Nakai K., Fujii H., Kono K., Goto S., Kitazawa R., Kitazawa S., Hirata M., Shinohara M., Fukagawa M., Nishi S. Vitamin D Activates the Nrf2-Keap1 Antioxidant Pathway and Ameliorates Nephropathy in Diabetic Rats. Am. J. Hypertens. 2013, 27:586-595.
5. Alsaad K.O., Herzenberg A.M. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J. Clin. Pathol. 2007, 60:18-26.
6. Cooper M.E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352:213-219.
7. Adler S. Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J. Am. Soc. Nephrol. 1994, 5:1165-1172.
8. Fridlyand L.E., Philipson L.H. Oxidative reactive species in cell injury: mechanisms in diabetes mellitus and therapeutic approaches. Ann. N. Y. Acad. Sci. 2005, 1066:136-151.
9. Kiritoshi S., Nishikawa T., Sonoda K., Kukidome D., Senokuchi T., Matsuo T., Matsumura T., Tokunaga H., Brownlee M., Araki E. Reactive o.xygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 2003, 52:2570-2577.
10. Lee E.A., Seo J.Y., Jiang Z., Yu M.R., Kwon M.K., Ha H., Lee H.B. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int. 2005, 67:1762-1771.
11. Thallas-Bonke V., Thorpe S.R., Coughlan M.T., Fukami K., Yap F.Y., Sourris K.C., Penfold S.A., Bach L.A., Cooper M.E., Forbes J.M. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008, 57:460-469.
12. Koya D., Hayashi K., Kitada M., Kashiwagi A., Kikkawa R., Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J. Am. Soc. Nephrol. 2003, 14:S250-S253.
13. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev. 2001, 17:189-212.
14. Lee H.B., Yu M.R., Yang Y., Jiang Z., Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:S241-S245.
15. Itoh K., Ishii T., Wakabayashi N., Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. Free Radic. Res. 1999, 31:319-324.
16. Jiang T., Huang Z., Lin Y., Zhang Z., Fang D., Zhang D.D. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59:850-860.
17. Cui W., Bai Y., Miao X., Luo P., Chen Q., Tan Y., Rane M.J., Miao L., Cai L. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxidative Med. Cell. Longev. 2012, 2012:821936.
18. de Haan J.B. Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes 2011, 60:2683-2684.
19. Zheng H., Whitman S.A., Wu W., Wondrak G.T., Wong P.K., Fang D., Zhang D.D. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011, 60:3055-3066.
20. Xue M., Qian Q., Adaikalakoteswari A., Rabbani N., Babaei-Jadidi R., Thornalley P.J. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008, 57:2809-2817.
21. Cho H.Y., Jedlicka A.E., Reddy S.P., Kensler T.W., Yamamoto M., Zhang L.Y., Kleeberger S.R. Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell Mol. Biol. 2002, 26:175-182.
22. Cho H.Y., Reddy S.P., Yamamoto M., Kleeberger S.R. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J. 2004, 18:1258-1260.
23. Shih A.Y., Li P., Murphy T.H. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J. Neurosci. 2005, 25:10321-10335.
24. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1814-1818.
25. Fan J.M., Ng Y.Y., Hill P.A., Nikolic-Paterson D.J., Mu W., Atkins R.C., Lan H.Y. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int. 1999, 56:1455-1467.
26. Wolf G. Growth factors and the development of diabetic nephropathy. Curr. Diab. Rep. 2003, 3:485-490.
27. Choi H.K., Pokharel Y.R., Lim S.C., Han H.K., Ryu C.S., Kim S.K., Kwak M.K., Kang K.W. Inhibition of liver fibrosis by solubilized coenzyme Q10: role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. Toxicol. Appl. Pharmacol. 2009, 240:377-384.
28. Susztak K., Bottinger E., Novetsky A., Liang D., Zhu Y., Ciccone E., Wu D., Dunn S., McCue P., Sharma K. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 2004, 53:784-794.
29. Kong L.L., Wu H., Cui W.P., Zhou W.H., Luo P., Sun J., Yuan H., Miao L.N. Advances in murine models of diabetic nephropathy. J. Diabetes Res. 2013, 2013:797548.
30. Susztak K., Sharma K., Schiffer M., McCue P., Ciccone E., Bottinger E.P. Genomic strategies for diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:S271-S278.
31. Wei W., Jin J., Schlisio S., Harper J.W., Kaelin W.J. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 2005, 8:25-33.
32. Ikuta K., Waguri-Nagaya Y., Kikuchi K., Yamagami T., Nozaki M., Aoyama M., Asai K., Otsuka T. The Sp1 transcription factor is essential for the expression of gliostatin/thymidine phosphorylase in rheumatoid fibroblast-like synoviocytes. Arthritis Res. Ther. 2012, 14:R87.
33. Wang Y., Zhang H., Chen Y., Sun Y., Yang F., Yu W., Liang J., Sun L., Yang X., Shi L., Li R., Li Y., Zhang Y., Li Q., Yi X., Shang Y. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009, 138:660-672.
34. Mittelstadt M.L., Patel R.C. AP-1 mediated transcriptional repression of matrix metalloproteinase-9 by recruitment of histone deacetylase 1 in response to interferon beta. PLoS ONE 2012, 7:e42152.
35. Eisermann K., Broderick C.J., Bazarov A., Moazam M.M., Fraizer G.C. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol. Cancer 2013, 12:7.
36. Nicolas M., Noe V., Jensen K.B., Ciudad C.J. Cloning and characterization of the 5'-flanking region of the human transcription factor Sp1 gene. J. Biol. Chem. 2001, 276:22126-22132.
37. Jochum W., Passegue E., Wagner E.F. AP-1 in mouse development and tumorigenesis. Oncogene 2001, 20:2401-2412.
38. Li L., Davie J.R. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann. Anat. 2010, 192:275-283.
39. Schuppan D., Krebs A., Bauer M., Hahn E.G. Hepatitis C and liver fibrosis. Cell Death Differ. 2003, 10(Suppl. 1):S59-S67.
40. Chuang J.Y., Wang Y.T., Yeh S.H., Liu Y.W., Chang W.C., Hung J.J. Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol. Biol. Cell 2008, 19:1139-1151.
41. Sharma K., Ziyadeh F.N. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 1994, 267:F1091-F1094.
42. Border W.A., Okuda S., Languino L.R., Sporn M.B., Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990, 346:371-374.